Zobrazeno 1 - 10
of 209
pro vyhledávání: '"Bauer-Mehren, A."'
Publikováno v:
Communications Medicine, Vol 1, Iss 1, Pp 1-10 (2021)
Plain language summary The clinical course of patients with COVID-19 is highly variable, with some patients barely affected and others dying. We wanted to better understand why this is the case and identify markers of COVID-19-associated mortality. T
Externí odkaz:
https://doaj.org/article/c84131697e1b4219b64e04fd36f36dbc
Autor:
Becker, T., Weberpals, J., Jegg, A.M., So, W.V., Fischer, A., Weisser, M., Schmich, F., Rüttinger, D., Bauer-Mehren, A.
Publikováno v:
In Annals of Oncology November 2020 31(11):1561-1568
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Artificial Intelligence, Vol 4 (2021)
Introduction: Prognostic scores are important tools in oncology to facilitate clinical decision-making based on patient characteristics. To date, classic survival analysis using Cox proportional hazards regression has been employed in the development
Externí odkaz:
https://doaj.org/article/3ea2c78de72443beaf43f1a7491a01e8
Autor:
Loureiro, Hugo, Roller, Andreas, Schneider, Meike, Talavera‐López, Carlos, Becker, Tim, Bauer‐Mehren, Anna
Publikováno v:
Clinical Pharmacology & Therapeutics; Feb2024, Vol. 115 Issue 2, p333-341, 9p
Autor:
Loureiro, Hugo, Kolben, Theresa M., Kiermaier, Astrid, Rüttinger, Dominik, Ahmidi, Narges, Becker, Tim, Bauer-Mehren, Anna
Publikováno v:
JCO Clinical Cancer Informatics; 11/3/2023, Vol. 7, p1-10, 10p
Publikováno v:
Medical Research Archives. 11
Background: Prognosis of overall survival is instrumental for patient management and can improve conduct of clinical trials and real-world data analysis. With the shift towards cancer immunotherapy, modeling of overall host fitness becomes increasing
Publikováno v:
Communications Medicine, Vol 1, Iss 1, Pp 1-10 (2021)
The COVID-19 pandemic represents a major public health threat. Risk of death from the infection is associated with age and pre-existing comorbidities such as diabetes, dementia, cancer, and impairment of immunological, hepatic or renal function. It r
BackgroundThe gold standard to evaluate treatment efficacy in oncology clinical trials is Overall Survival (OS). Its utility, however, is limited by the need for long trial duration and large sample sizes. Thus methods such as Progression-Free Surviv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4eb1ffcdf004fc888a0b58215f3ae365
https://doi.org/10.1101/2022.10.11.22280399
https://doi.org/10.1101/2022.10.11.22280399
Autor:
Risselada, R., Lingsma, H. F., Bauer-Mehren, A., Friedrich, C. M., Molyneux, A. J., Kerr, R. S. C., Yarnold, J., Sneade, M., Steyerberg, E. W., Sturkenboom, M. C. J. M.
Publikováno v:
European Journal of Epidemiology, 2010 Jan 01. 25(4), 261-266.
Externí odkaz:
https://www.jstor.org/stable/40602618